These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17990181)

  • 21. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
    Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
    Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
    Jäeger G; Neumeister P; Brezinschek R; Höfler G; Quehenberger F; Linkesch W; Sill H
    Eur J Haematol; 2002 Jul; 69(1):21-6. PubMed ID: 12270058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases.
    Wöhrer S; Troch M; Zwerina J; Schett G; Skrabs C; Gaiger A; Jaeger U; Zielinski CC; Raderer M
    Ann Oncol; 2007 Apr; 18(4):647-51. PubMed ID: 17218490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
    Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL.
    Fisher RI
    Clin Adv Hematol Oncol; 2005 Jul; 3(7):544-6. PubMed ID: 16167036
    [No Abstract]   [Full Text] [Related]  

  • 28. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma.
    Aguiar Bujanda D; Aguiar Morales J; Bohn Sarmiento U; Saura Grau S; Rodríguez Franco C
    Clin Transl Oncol; 2009 Sep; 11(9):604-8. PubMed ID: 19776000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
    Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
    Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
    Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. R-CHOP therapy for MALT lymphoma of the rectum.
    Chihara D; Kagami Y; Oki Y; Kato H; Onoda H; Ine S; Taji H; Yamamoto K; Morishima Y
    Eur J Haematol; 2010 Jan; 84(1):84-6. PubMed ID: 19737307
    [No Abstract]   [Full Text] [Related]  

  • 35. Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
    Lee GW; Kang JH; Kim IS; Kim HG; Ko GH; Lee JH; Kim DC; Song DH; Yang JW; Lee JS
    Leuk Lymphoma; 2009 Dec; 50(12):1992-8. PubMed ID: 19860620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
    Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
    Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
    [No Abstract]   [Full Text] [Related]  

  • 37. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
    Hiddemann W; Kneba M; Dreyling M; Schmitz N; Lengfelder E; Schmits R; Reiser M; Metzner B; Harder H; Hegewisch-Becker S; Fischer T; Kropff M; Reis HE; Freund M; Wörmann B; Fuchs R; Planker M; Schimke J; Eimermacher H; Trümper L; Aldaoud A; Parwaresch R; Unterhalt M
    Blood; 2005 Dec; 106(12):3725-32. PubMed ID: 16123223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Xu W; Li JY; Zhang ZH; Qiu HX; Qian SX; Wu HX; Lu H; Sheng RL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):933-7. PubMed ID: 18718094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
    Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.